Miraculins Inc.

Miraculins Inc.

March 30, 2005 08:30 ET

Miraculins Announces Positive Results of Study to Improve the Diagnosis of Prostate Cancer


NEWS RELEASE TRANSMITTED BY CCNMatthews

FOR: MIRACULINS INC.

TSX VENTURE SYMBOL: MOM

MARCH 30, 2005 - 08:30 ET

Miraculins Announces Positive Results of Study to
Improve the Diagnosis of Prostate Cancer

WINNIPEG, MANITOBA--(CCNMatthews - March 30, 2005) - Miraculins Inc.
(TSX VENTURE:MOM), a biotechnology company engaged in the discovery and
development of products for select cancers, is pleased to announce the
positive results of the Company's prostate cancer study initiated in the
summer of 2004. The study compared asymptomatic (healthy) patients and
those patients diagnosed with Benign Prostatic Hyperplasia (BPH) with
those positive for prostate cancer using the Company's proprietary
BEST™ platform.

The clinical investigation, conducted by Miraculins in cooperation with
the Edmonton Prostate and Urological Research Centre and the Winnipeg
Clinic, confirmed the interim findings reported in the Company's press
release of December 13, 2004. Specifically, the study used samples from
110 patients. By using Miraculins diagnostic approach, the Company was
able to correctly identify cancer positives while correctly classifying
those without cancer with a sensitivity and specificity of greater than
90%-90%. All samples in the prostate cancer study have been provided
through patient contact with participating urologists and are supplied
with complete clinical and PSA data.

Miraculins' numbers are a significant improvement over the documented
numbers for the Prostate Specific Antigen (PSA) Test, the standard
screen for prostate cancer in men. Using a clinically accepted cut off
of 4 ng/mL in blood, the PSA test has been shown in the literature to
have a sensitivity of roughly 85% and a specificity of only 33%. This is
representative of the fact that a majority of men who have elevated PSA
levels do not actually have prostate cancer. Many of these men would be
subsequently referred for an unnecessary prostate biopsy as a result of
the poor specificity of the PSA test. By improving the specificity to
greater than 90%, Miraculins test would be able to reduce the number of
false positives dramatically.

"We see our diagnostic as a follow-up product for men with an unclear
diagnosis based on PSA levels. A considerable opportunity exists to
positively impact patient care by eliminating the need for the vast
number of biopsies that are unnecessary", stated Dr. Jim Charlton,
President of Miraculins. "These biopsies place a significant strain on
the healthcare system and the patient at a cost of roughly $2,000 per
procedure. A product that can aid men in this uncertain situation has
substantial value".

The BEST™ platform utilizes the concurrent analysis of clinical
factors and biological data, and a combination of proteomic, mass
spectrometric, and protein chemistry techniques for biomarker discovery.
This is then followed by rigorous bioinformatic and statistical
evaluation resulting in a panel of markers and factors the Company has
shown can improve the diagnosis of a given state of health.

"The results to date are consistent with our confidence that the
BEST™ platform can be used to develop improved means of cancer
diagnosis", continued Charlton. "We are encouraged by the results of the
completed study of our prostate cancer diagnostic and the results of the
next phase of development will give us the information to develop the
program for FDA approval, and move into partnership and
commercialization."

This prostate cancer study represents the lead project for Miraculins
and the Company continues to evaluate opportunities to expand its focus
by initiating studies in additional disease conditions. In January,
Miraculins announced the initiation of its Breast Cancer discovery
program. The Company expects to begin looking at additional cancer types
in the coming months.

About Miraculins Inc.

Miraculins is a biotechnology company focused on research and
development using its proprietary BEST™ platform for the screening
and identification of target proteins and peptides related to diseases.
The Company is developing products for the diagnosis and treatment of
select cancers. Its lead product focuses on improving the diagnosis of
prostate cancer.

Prostate cancer is responsible for greater than 240,000 new diagnoses in
North America each year. The current screening standard for prostate
cancer, PSA, is ineffective at reliably distinguishing between non-life
threatening prostate conditions and critical prostate cancer. In spite
of this fact, there are greater than 25 million PSA tests performed
annually in the United States alone, resulting in one million prostate
biopsy procedures. An estimated 75% of these procedures are unnecessary
and could be avoided if a superior alternative to PSA was available.

Certain information contained in this press release may be
forward-looking and is subject to risks and uncertainties. Although the
Company believes that the expectations contained herein are reasonable,
it can give no assurances such forward-looking statements will prove
correct. Information is provided from sources deemed to be reliable.

-30-

Contact Information

  • FOR FURTHER INFORMATION PLEASE CONTACT:
    Miraculins Inc.
    Michael Coutts
    Investor Relations
    (204) 487-2328
    (204) 488-9823 (FAX)
    info@miraculins.com
    www.miraculins.com
    The TSX Venture Exchange has neither approved nor disapproved the
    contents of this press release.